Latest news about Bal Pharma
Bal Pharma
106.21
-8.24(-7.20%)
Company Performance:
View Company Insights1D-7.20%
1M+19.03%
6M+53.68%
1Y+19.93%
5Y+6.21%
More news about Bal Pharma
28Jul 26
Bal Pharma Q4 Results: Net profit falls 34% YoY to ₹370 lakh
Bal Pharma Limited reported a Q4FY26 standalone net profit of ₹370.02 lakh, down 34% YoY, despite a slight revenue increase to ₹8,391.76 lakh. Full-year profit declined to ₹675.12 lakh. The Board recommended a Re.1 dividend per share and approved new stock options and warrant issues.
09Jul 26
Bal Pharma seeks approval to issue warrants to promoter
Bal Pharma is seeking shareholder approval via postal ballot to issue 10,00,000 warrants to promoter Mr. Shailesh Siroya at ₹81 per warrant, aggregating ₹8.10 crore. The proceeds will fund a new API manufacturing facility in Yadagiri, Karnataka. The e-voting process runs from July 10 to August 08, 2026, with results expected by August 11, 2026. The conversion of warrants will increase the promoter's stake from 17.24% to 22.13%.
25Jun 26
Bal Pharma appoints Shreepada ML as Company Secretary
Bal Pharma Ltd announced the appointment of Mr. Shreepada ML as Company Secretary and Compliance Officer, effective June 23, 2026, to oversee regulatory compliance and corporate governance.
30May 26
Bal Pharma FY26 net profit falls 13.4%, announces dividend
Bal Pharma reported a 13.4% decline in FY26 net profit to ₹675.12 lakh, while revenue from operations increased 2.7% to ₹31,079.70 lakh. The board recommended a ₹1.20 dividend and approved a preferential issue of warrants to promoters, alongside employee stock options. The audited results were published in newspapers on May 29, 2026.
12May 26
Bal Pharma's Company Secretary & Compliance Officer Abdul Basith Resigns Effective May 11, 2026
Bal Pharma Limited has disclosed the resignation of Mr. Abdul Basith (Membership No. A70640), Company Secretary & Compliance Officer, effective close of business hours on May 11, 2026. Mr. Basith submitted his resignation on March 2, 2026, citing a decision to pursue external career opportunities, and the resignation was accepted on May 11, 2026. The company has directed all secretarial communications to secretarial@balpharma.com until a new Company Secretary & Compliance Officer is appointed. The intimation was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
06Apr 26
Bal Pharma Limited Confirms Compliance with SEBI Dematerialization Regulations for Q4 FY26
Bal Pharma Limited has confirmed compliance with SEBI (DP) Regulations 74(5) for the quarter ended March 31, 2026. The company submitted details of securities dematerialized/rematerialized during the quarter to stock exchanges within prescribed time limits. The confirmation, signed by authorized signatory Shailesh Siroya, was communicated to NSE, BSE, and both depositories NSDL and CDSL.
11Feb 26
Bal Pharma Q3FY26 Results: Net Profit Surges 181.84% YoY to ₹194.62 Lakhs
Bal Pharma Limited delivered outstanding Q3FY26 results with net profit jumping 181.84% year-on-year to ₹194.62 lakhs, while revenue from operations grew 20.03% to ₹8,749.48 lakhs. The company's Board of Directors approved the unaudited financial results during their meeting on February 11, 2026, with statutory auditors SSJNB & Co providing an unmodified opinion, demonstrating strong operational efficiency and regulatory compliance.
08Jan 26
Bal Pharma Issues Postal Ballot Notice for Independent Director Appointment
Bal Pharma Limited has initiated a postal ballot process for shareholder approval of Dr. Mukesh Beekamchand's appointment as Independent Director for a five-year term. The e-voting period runs from January 9-February 7, 2026, with results expected by February 10. This follows the company's Q2 financial results showing revenue of ₹7,374.95 lakhs and net profit of ₹78.17 lakhs.
07Nov 25
Bal Pharma Defers Subsidiary Merger Decision, Citing Need for More Data
Bal Pharma Limited has postponed its decision on the proposed merger of its subsidiary, Lifezen Healthcare Pvt Ltd, with the parent company. The Board of Directors found the available data inadequate for making an informed decision during their recent meeting. The management has been instructed to re-present the proposal with all necessary details. The board meeting was held on 11.08.2025, and the company provided clarification to the stock exchange on 06.11.2025 regarding the deferred decision.
11Aug 25
Bal Pharma Reports Q1 FY2026 Results, Approves Employee Stock Option Plan
Bal Pharma Limited released its Q1 FY2026 financial results. Standalone revenue from operations was ₹6563.51 lakhs with a net profit of ₹32.31 lakhs. Consolidated revenue stood at ₹6587.09 lakhs with a net profit of ₹20.85 lakhs. The company announced its 38th AGM for September 25, 2025, to be held virtually. Book closure dates are set from September 19 to 25, 2025. The Board approved an Employee Stock Option Plan-2025, subject to shareholder approval. Auditors provided an unmodified opinion on the financial results. The company continues to operate in the 'Pharmaceuticals' segment.
29Jul 25
Bal Pharma Schedules Board Meeting to Discuss Q1 Results, ESOP, and Subsidiary Merger
Bal Pharma has scheduled a Board of Directors meeting for August 11, 2025, with a comprehensive agenda. Key items include reviewing Q1 financial results, planning the 38th AGM, considering an Employee Stock Option Plan-2025, and potentially merging subsidiary Lifezen Healthcare Pvt Ltd. A trading window closure is in effect from June 1 to August 14, 2025, for designated persons and employees.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Laurus Labs
Aurobindo Pharma
Dr Reddys Laboratories
Lupin
Mankind Pharma
1,861.00
(-0.21%)
9,438.50
(-0.52%)
4,930.00
(0.0%)
1,117.80
(-0.85%)
1,373.30
(+0.75%)
1,945.00
(+0.41%)
1,668.40
(-1.80%)
1,143.00
(-0.17%)
2,077.80
(-1.06%)
2,238.40
(-1.17%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
